| No opting out/total no in category (%) | Univariate OR (95% CI) | Adjusted OR† (95% CI) | p Value | |
| New consultations | 640/10 673 (6.0) | |||
| Sex | ||||
| Male (vs female) | 349/4584 (7.6) | 1.64 (1.40 to 1.93) | 1.39 (1.16 to 1.67) | |
| Age median (tested 26 (IQR 22–34) not tested 29 (IQR 24–38)) | ||||
| Mean age, years | ||||
| <29 | 331/6748 (4.9) | 1 | 1 | |
| 30–39 | 163/2392 (6.8) | 1.42 (1.17 to 1.72) | 1.35 (1.11 to 1.66) | <0.001 |
| 40–49 | 108/1075 (10.0) | 2.17 (1.73 to 2.72) | 2.03 (1.60 to 2.56) | <0.001 |
| ⩾50 | 38/459 (8.3) | 1.75 (1.23 to 2.48) | 1.51 (1.05 to 2.14) | <0.001 |
| Ethnicity | ||||
| Dutch | 376/6751 (5.6) | 1 | 1 | |
| Other | 96/1746 (5.5) | 0.99 (0.78 to 1.24) | 0.91 (0.71 to 1.17) | |
| Sub-Saharan African | 51/455 (11.2) | 2.14 (1.57 to 2.92) | 1.96 (1.42 to 2.70) | <0.001 |
| Northern African | 16/219 (7.3) | 1.33 (0.80 to 2.25) | 1.09 (0.64 to 1.84) | |
| Turkish | 13/139 (9.4) | 1.75 (0.98 to 3.13) | 1.24 (0.69 to 2.24) | |
| Surinam/Antillean | 88/1364 (6.5) | 1.17 (0.92 to 1.49) | 1.18 (0.92 to 1.51) | |
| HIV test | ||||
| Never been tested before (vs ever tested) | 304/4048 (7.5) | 1.52 (1.30 to 1.78) | 1.65 (1.40 to 1.95) | |
| Triage items* | ||||
| STI-related complaints (vs no complaints) | 482/6841 (7.0) | 1.73 (1.44 to 2.08) | 1.67 (1.38 to 2.02) | |
| Notified by sexual partner (vs not notified) | 85/1615 (5.3) | 0.85 (0.67 to 1.08) | – | |
| Receiving payment for sex (vs no payment) | 53/802 (6.6) | 1.12 (0.84 to 1.50) | 1.70 (1.21 to 2.38) | |
| Diagnoses at consultation* | ||||
| Gonorrhoea (vs no gonorrhoea) | 23/315 (7.3) | 1.24 (0.81 to 1.92) | – | |
| Chlamydia (vs no chlamydia) | 87/1822 (4.8) | 0.75 (0.60 to 0.95) | – | |
| Hepatitis B carrier (vs no carrier) | 10/78 (12.8) | 2.33 (1.19 to 4.54) | – | |
| Infectious syphilis (vs no infectious syphilis) | 4/25 (16.0) | 2.99 (1.03 to 8.76) | – | |
| Genital HSV I/II (vs no HSV) | 26/286 (9.1) | 1.59 (1.06 to 2.40) | 1.62 (1.07 to 2.45) | |
| Genital warts (vs no warts) | 32/574 (5.6) | 0.92 (0.64 to 1.33) | – | |
| Non-specific ulcus (vs no or specific ulcus) | 9/129 (7.0) | 1.18 (0.60 to 2.33) | – | |
| Vaginal sex | ||||
| No vaginal sex or vaginal sex with condom | 121/1500 (8.1) | 1 | 1 | |
| Unprotected vaginal sex casual partner only | 207/3782 (5.5) | 0.66 (0.52 to 0.83) | 0.74 (0.58 to 0.95) | <0.001 |
| Unprotected vaginal sex steady partner only | 228/3602 (6.3) | 0.77 (0.61 to 0.97) | 0.79 (0.62 to 1.00) | |
| Unprotected vaginal sex casual plus steady partners | 84/1790 (4.7) | 0.56 (0.42 to 0.75) | 0.60 (0.44 to 0.80) | <0.001 |
| Anal sex | ||||
| No anal sex or anal sex with condom | 569/8714 (6.5) | 1 | 1 | |
| Unprotected anal sex casual partner only | 25/823 (3.0) | 0.45 (0.30 to 0.67) | 0.62 (0.41 to 0.95) | <0.001 |
| Unprotected anal sex steady partner only | 45/1039 (4.3) | 0.65 (0.48 to 0.88) | 0.77 (0.56 to 1.07) | |
| Unprotected anal sex casual plus steady partners | 1/98 (1.0) | 0.15 (0.02 to 1.06) | 0.19 (0.03 to 1.41) | |
| Injecting drug use | 2/21 (9.5) | 1.65 (0.38 to 7.11) | – |
*Visitors may score on several items; †Odds ratios (OR) in the multivariate model are adjusted for all factors for which adjusted OR are shown. HSV, herpes simplex virus; IQR, interquartile range; STI, sexually transmitted infection.